acid, methylparaben, potassium sorbate, and simethicone) was then geometrically incorporated to a final volume of 250 mL.
Each preparation was packaged in 50-mL amber plastic bottles (6 bottles containing 30 mL per preparation; polyethylene terephthalate [PET] with black phenolic cap, Medisca Pharmaceutique Inc) and 3-mL amber polypropylene syringes (48 syringes containing 1 mL per preparation; PreciseDose syringes with tip cap, Medisca Pharmaceutique Inc). Three bottles of each preparation and 3 syringes for each time point were stored at a mean temperature of 5°C (standard deviation [SD] 2°C) or 25°C (SD 2°C), with relative humidity 60% (SD 5%). At predetermined time points (0, 7, 14, 30, 45, 60, 75, and 90 days), a 1-mL aliquot was retrieved from each bottle and 3 syringes were retrieved from each temperature condition. The bottles and syringes were vigorously shaken until complete resuspension before sampling.
On each study day, the appearance of each test sample was inspected. The pH was evaluated (pH 211 model pH meter, Hanna Instruments, Montréal, Quebec) and concentration was For the HPLC analysis, each test sample (50 µL) was diluted with methanol (950 µL) in a 1.5-mL centrifuge tube, vortexed (20 s) and then centrifuged (10 000g for 10 min). The supernatant (150 µL) was further diluted using a mixture of acetonitrile and water (20:80, 150 µL) and vortexed (20 s). These solutions for injection (nominal 0.05 mg/mL) were analyzed immediately after preparation using an HPLC system (Prominence UFLC, Shimadzu, Laval, Quebec) equipped with an LC-20AD binary pump, a DGU-20A5 solvent degasser, an SPD-M20A multiplewavelength photodiode array detector set at 290 nm, an SIL-20AC HT refrigerated autosampler set at 5°C, a CTO-20AC column oven set at 40°C, and a Kinetex XB-C18 column (4.6 × 100 mm, 5 µm, Phenomenex Inc, Torrance, California). An isocratic method (acetonitrile-aqueous KH 2 PO 4 10 mmol/L, 12:88, 1 mL/min) was used. The dapsone peak eluted at approximately 7.1 min; the peak area was used to perform the quantification. Injections (10 µL) were performed in duplicate for test samples and in triplicate for standard samples.
To perform the calibration, standard suspensions of dapsone bulk powder (AK Scientific, Union City, California; lot 90411H, expiry May 2019) in Oral Mix and Oral Mix SF were prepared as described above, diluted to concentrations of 1.6, 1.8, 2.0, 2.2, and 2.4 mg/mL (80% to 120% of the target concentration), and analyzed by HPLC (r 2 not less than 0.999). The 2 mg/mL standard was also injected after every 24 injections of test solution to ensure system stability. The highest intraday coefficient of variation observed was 1.65% (n = 3), and the highest interday coefficient of variation was 1.82% (over 3 days; n = 3 × 3) at the target concentration.
Forced degradation at 60°C for 3 h in one volume each of purified water, hydrogen peroxide 3%, sodium hydroxide 1 mol/L, and hydrochloric acid 1 mol/L resulted in recoveries of 76%, 73%, 91%, and 69%, respectively. No peak overlap of dapsone with excipients, impurities, or degradation products was observed. All non-dapsone peaks eluted between 1 and 5 min. Dapsone peak purity index calculated between 260 and 320 nm was not less than 0.9999 in all cases. 3 Representative chromatograms are presented in Figure 1 .
For all suspensions, no notable changes in odour or colour were observed after storage under different conditions for 90 days. The suspensions remained opaque beige with a sweet aroma, but settling was observed after a few days. As shown in Table 1 , the concentration of dapsone was not less than 90% of the initial concentration for all preparations at each tested condition, except suspensions in Oral Mix stored at 25°C for 7 days or longer. The difference in pH relative to the initial pH was not more than 0.5 unit for all preparations at all tested conditions (mean initial pH 4.18 [SD 0.03] for suspensions in Oral Mix and 4.43 [SD 0.03] for suspensions in Oral Mix SF).
The instability of dapsone suspensions prepared in Oral Mix and stored at 25°C may be explained by a Maillard reaction between the sucrose in the vehicle and the amino groups of the dapsone. 9 Storage under refrigeration prevented this reaction. Therefore, to avoid the Maillard reaction, Oral Mix SF should be preferred over other sugar-containing vehicles.
The results of this study have demonstrated the stability, for up to 90 days, of dapsone suspensions (2 mg/mL) prepared from commercial tablets in Oral Mix SF and stored at 5°C and 25°C or prepared in Oral Mix and stored at 5°C, in amber plastic bottles and amber plastic syringes. These suspensions should be shaken before use.
